CriticalProkinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)×Class III antiarrhythmic
Updated · Methodology
Mechanism
Dronedarone itself prolongs the QT interval, by about 10 ms with the Bazett formula, and this is linked to its therapeutic effect on cardiac repolarisation (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). The dronedarone SmPC lists cisapride among drugs that can induce torsade de pointes and contraindicates them because of the risk of proarrhythmia (dronedarone SmPC, EMA). Dronedarone is also a moderate CYP3A4 inhibitor (dronedarone SmPC, EMA). The dronedarone documents do not say how this changes cisapride levels. With erythromycin, another moderate CYP3A4 inhibitor, blood levels of cisapride rose (erythromycin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Symptoms
The main danger of the combination is torsade de pointes–type ventricular tachycardia (dronedarone label, US Food and Drug Administration, FDA). High cisapride levels can cause QT prolongation, ventricular tachycardia and ventricular fibrillation (erythromycin summary of product characteristics, SmPC, on its combination with cisapride, Spanish Agency of Medicines and Medical Devices, AEMPS). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while a ventricular arrhythmia causes sudden strong palpitations, dizziness or fainting and can lead to cardiac arrest. According to the dronedarone SmPC, proarrhythmic effects can occur when it is taken with drugs that favour arrhythmias or when there are electrolyte disorders (European Medicines Agency, EMA).
Management
The combination is contraindicated. The dronedarone summary of product characteristics (SmPC) puts cisapride on the list of drugs that can induce torsade de pointes and are contraindicated with dronedarone (dronedarone SmPCs, European Medicines Agency, EMA, and Spanish Agency of Medicines and Medical Devices, AEMPS). The US dronedarone label contraindicates drugs that prolong the QT interval and might increase the risk of torsade de pointes; cisapride is not among its examples (dronedarone label, US Food and Drug Administration, FDA). Cisapride is not in the Spanish medicines register CIMA, so the level of risk comes from the dronedarone documents. If a person takes cisapride obtained in another country, do not prescribe dronedarone with it (dronedarone SmPC, EMA). If any of the circumstances listed among the contraindications develops during treatment, stop dronedarone (dronedarone SmPC, EMA). Correct any potassium or magnesium deficiency before and during dronedarone treatment. The SmPC recommends monitoring during treatment, including an electrocardiogram (ECG). Stop dronedarone if the corrected QT interval (QTc, Bazett) is 500 ms or longer (dronedarone SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Multaq (dronedarone) prescribing information (2025)– FDA, DailyMed setid 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (Sanofi-Aventis U.S.), version 37, revised 05/2025, sections 4, 5.8 and 7
- AEMPS: Ficha técnica: Dronedarona (nº registro 84320), sección 4.3 (2025)– AEMPS, CIMA, nº registro 84320, revisión 10/2025, sección 4.3
- EMA: Ficha técnica: Dronedarona, Multaq 400 mg (EU/1/09/591) (2024)– EMA SmPC vía AEMPS CIMA, nº registro 09591003 (Multaq 400 mg comprimidos recubiertos con película, EU/1/09/591), revisión del texto 07/2024, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Eritromicina (nº registro 55771), sección 4.5 (2025)– AEMPS, CIMA, nº registro 55771 (Pantomicina 1 g polvo para solución para perfusión, Amdipharm), revisión 09/2025 (texto revisado 02/2023), secciones 4.4 y 4.5